Search
Insilico Medicine: Establishes Strategic Drug Development Collaboration with China Medical System Holdings
1 day ago /
Read about 0 minute
Author：小编
On February 10, 2026, Insilico Medicine announced on the Hong Kong Stock Exchange that it has entered into a strategic drug development collaboration with China Medical System Holdings. The two parties will engage in AI-enabled innovative drug development in the areas of central nervous system and autoimmune diseases, jointly advancing no fewer than two R&D projects. Insilico Medicine is expected to receive research and development funding support of up to tens of millions of Hong Kong dollars for each project.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
